

Date: 8 March 2022

Re: Freedom of Information Request
Ref: 48 -2022

Thank you for your email dated the 18/2/2022, requesting information in relation to breast cancer treatments.

The information that you require is as follows:

1st December 2021 – 28th February 2022

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent	The Trust only record if this is a first intervention – this information is not held	
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0	patients
Abemaciclib + Fulvestrant	10	patients
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	1	patients
Atezolizumab +Nab-paclitaxel/Paclitaxel	0	patients
Capecitabine as a single agent	19	patients
Carboplatin or Cisplatin as a single agent	3	patients
Eribulin as a single agent or in combination	4	patients
Everolimus + Exemestane	0	patients
Fulvestrant as a single agent	0	patients
Lapatinib	0	patients
Neratinib	2	patients
Parp Inhibitors (Olaparib/Talazoparib)	0	patients
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0	patients
Palbociclib + Fulvestrant	14	patients
Pembrolizumab	0	patients

Pertuzumab + Trastuzumab + Docetaxel	0	patients
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0	patients
Ribociclib + Fulvestrant	0	patients
Sacituzumab Govitecan	0	patients
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	116	patients
Trastuzumab as a single agent or in combination	84	patients
Trastuzumab emtansine	0	patients
Transtuzumab deruxtecan	4	patients
Vinorelbine as a single agent	0	patients
Any other active systemic anti-cancer therapy	Number of patients	
Abemaciclib	10	
AC-Taxol regiment (Adriamycin and cyclophosphamide followed by Taxol)	1	
Aspirin/placebo (ADD Aspirin Trial)	6	
Atezolizumab	2	
Atezolizumab/Paclitaxel Albumin	4	
Cyclophosphamide + Docetaxel	2	
Denosumab	128	
Epirubicin Cyclophosphamide	108	
Epirubicin	1	
Epirubicin (weekly)	2	
Eribulin	4	
EVEROLIMUS	4	
Faslodex	11	
GemCarbo Days 1+8	2	
KADCYLA (TRAST EMT LD)	6	
KADCYLA (TRAST EMT MT)	20	
LETROZOLE	1	
Neratinib	2	
OP FASLODEX	3	
OP PALBOCICLIB	2	
OP PERTUZUMAB (LOAD)	2	
OP PERTUZUMAB (MAINT)	2	
Paclitaxel+Pertuzumab+Trastuz SC	29	
Palbociclib	79	
Palbociclib (NEO21 RS Trial)	3	
Palbociclib + Fulvestrant	14	
PERT TRAST (PHESGO)	4	
PERTUX TRAST (MT)	1	
Pertuzumab + Trastuzumab IV	4	
PHESGO	56	

Ribociclib	5	
Trastuzumab(Kadcyla®) (Load)	2	
Trastuzumab(Kadcyla®) (Maintenance)	7	
Zoladex	141	
Zoledronate	427	

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?

The Trust only record whether this is a first intervention – this information is not held.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net